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MATTERS 
ARISING
Pain in the rheumatic 
diseases
We were very interested to read Professor 
Croft’s article1 about pain in the rheumatic 
diseases because we are interested in studying 
the relation between patients’ perception of 
disease and objective signs.2 In the daily 
management of a cohort of approximately 
600 patients with inflammatory arthritis at 
Poole Hospital we noticed a dissociation 
between reported pain and objective 
measures o f  disease activity in a number o f  
patients.
To further study this phenomenon we ran­
domly selected a sample of 100 patients wirh 
rheumatoid arthritis (mean (SD) age = 63 
(12) years, 73% rheumatoid factor positive). 
We looked at the pattern o f change o f  
reported pain (10 cm visual analog scale 
(VAS)), number of swollen joints (EULAR  
28 articular index), and serum C reactive 
protein (CRP, normal <10 mg/1) in the previ­
ous two years.
We identified a close linear relation in 72 
patients. In 18 patients pain was repeatedly 
reported at not less than 20 mms VAS despite 
no evidence of disease activity (CRP <10  
mg/1 and swollen joint count = 0) at any point 
during their follow up. In 10 patients pain 
was repeatedly scored as absent despite 
disease activity markers reflecting joint 
inflammation (CRP >15 mg/1, with or 
without >2 swollen joints). Fifteen o f 18 
patients showing pain but no disease activity 
were rheumatoid factor positive and there 
was no obvious difference in the degree of  
joint deformity clinically although detailed 
assessment o f  joint damage radiologically was 
not made.
These preliminary data support our 
contention that, in about one third of patients 
followed up in a district general hospital 
there is a dissociation between reported pain 
and objective signs of joint inflammation. 
These differences may be related to joint 
damage in the patients with pain but no dis­
ease activity but cannot be so explained in 
those patients with disease activity but no 
pain. A more detailed analysis of these 
patients may reveal the reasons for this disso­
ciation. In the meantime we suggest that 
rheumatologists might consider managing 
pain separately from disease activity in some 
of their patients. We also urge caution in 
interpreting summated disease activity 
indices that include pain and joint tenderness 
as major parts of their score.
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Antiperinuclear factors 
are present in 
polyarthritis before ACR 
criteria for rheumatoid 
arthritis are fulfilled
We were interested in the study by Berthelot 
and colleagues, in which they studied the 
predictive value of the antiperinuclear factor 
(APF) for rheumatoid arthritis,1
The authors concluded that APFs are use­
ful in the diagnosis of early rheumatoid 
arthritis. They mentioned that recognition of 
the true value of APF has long been hindered 
by metiiodical errors. Serum samples were 
only diluted 1:5 or 1:10j even diough the 
APF titre can reach 1:20 000 in rheumatoid 
artritis serum samples and is usually above 
1:200.
We would like to make some comments 
especially concerning the method they used. 
The method used differs not only in the dilu­
tion of the serum samples, for screening 
1:100 and if positive they were farther diluted 
1:200, 1:500, 1:1000 to determine the end 
point titre, but it differs also in the way of 
regarding the positivity o f the tests. They 
refer to their study published in 1990, in 
which a dilution of 1:80 is used. In 1990 
Westgeest et al described for the first time the 
influence of serum dilution on findings of the 
APF prevalence in rheumatoid arthritis 
(RA).2 So authors of the study on an 
interlab oratory variability test for RA (1993) 
from the representing laboratories in Amster­
dam, Brest, Gent, and Nijmegen came 
together to discuss their different methods 
for the APF determination and to reach a 
standard protocol. This protocol was used for 
a quantitative assessment of the method, 
using the WHO standard rheumatoid artritis 
serum as a reference serum. The results of 
coded serum samples from five separate 
patients were blindly tested in the five labora­
tories. The methods used were not 
harmonised. Four laboratories defined the 
titre of a serum by the highest dilution, which 
gave a clearly positive result, while the 
laboratory in Brest, to which Berthelot and 
colleagues also refer, also considered the per­
centage o f cells that were stained. 1 The 
results of the five laboratories showed only 
small interlaboratory variations. The inter- 
laboratory variations were again reduced by 
comparison with the results with the WHO 
standard rheumatoid arthritis serum and 
thereby expressing the results in IU instead of 
litres, this study is not mentioned in Dr 
Berthelot*» study.1 So linked to die 
uniformity of the results, we think that die 
value of the APF is not hindered by the 
method.
In our longitudinal evaluation during 
methotrexate and azathioprine treatment for 
RA, the highest APF titre was 1:640.,l In the 
study by Berdielot et al the APF titre can 
reach 1:20 000 in rheumatoid arthritis serum 
samples.
Did Berthelot and colleagues use another 
method than that they used in the 
intervariability study?
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Authors’ reply
We gratefully acknowledge Dr Boerbooms 
for her valuable comments on our 
antiperinuclear factor (APF) paper.1 Her 
statement is correct. Five European groups 
set up a consensus study on the 
interlaboratory variability of the APF test in 
1993.2 Despite the use of different cells, con­
jugates, and criteria for positivity, their results 
were comparable for the five serum samples 
tested. Given that there is a risk that any arte­
fact could be mistaken for a stained granule, 
we feel, however, that it is useful to take into 
account the proportion o f stained cells,3 as 
suggested by others,'1 Similarly Dr Westgeest 
and Boerbooms underlined themselves the 
importance of serum dilution,'1 the same year 
when Youinou et al proposed to increase it up 
to 1:80 instead of 1\5.4 We recently identified 
anodier source of poor results (that is, to 
delay the test several days after fixation of the 
slides)/ Regarding our much better 
sensitivity. Dr Boerbooms is also aware that 
the suitability of particular buccal mucosa 
cells is unpredictable. The possibility 
therefore exists that donors vary from one 
country or laboratory to another, and 
actually more than 70% of our donor’s cells 
exhibit large granules. We fully agree with Dr 
Boerbooms that die APF test warrants being 
used on a regular basis. We recently came 
across the literature and believe that the APF 
test has been underevaluated. To conclude, 
we thank Dr Boerbooms for the opportunity 
to debate these technical details, although we 
quite respect her choice o f an older but still 
valuable method: for instance Westgeest and 
Boerbooms could confirm the findings of 
Katahaa7 that APF can also be found in some 
infectious mononucleosis serum samples, 
and suggested that Kpstein-Barr virus might 
be a co-factor in the breakdown of tolerance 
towards profilaggrin/ Although direct 
evidence for this assumption is still lacking, 
our recent findings of a strong T  cell response 
towards Epstein-Barr virus lytic cycle 
antigens in RA joints might indicate that their 
hypothesis was correct.*
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LETTER
rhG-CSF resistant 
neutropenia in SLE
Suppression o f die haematopoietic system, 
especially o f die myeloid lineage, is a severe 
complication of systemic lupus erythemato­
sus (SLE) .1 In a recent report Euler et at sug­
gested rhG-CSF as an effective treatment of  
neutropenia during SLE, especially during 
infection resistant to antibiotic treatment/ 
We present a case o f a girl with SLE whose 
neutropenia did not respond to rhG-CSF  
and who subsequently succumbed to 
untreatable fungal sepsis.
A previously healthy 9,5 year old girl 
developed SLE presenting with six o f 1 1 cri­
teria of the American College of Rheumatol­
ogy including butterfly rash, oral ulcers, 
arthritis, and serosids. Laboratory investiga­
tions demonstrated ANA+, anti-dsDNA+, 
hypocamplementacmia, but normal white 
blood cell count, Eight months after initial
remission she had a relapse, presenting with 
neutropenia (650 neutrophils/ill, 800 
lymphocytes/|.tl) and signs of nephritis. Bone 
marrow biopsy examination showed a general 
suppression of all myeloid lineages including 
megacaryocytes but showed a relative 
increase of the red blood cell lineage. Over 
the next months neutropenia was resistant to 
several pulses of intravenous mediylpred- 
nisolone therapy (250 mg/day), to cyclophos­
phamide intravenous pulse treatment (500  
mg/m2)» and to intravenous IgG therapy 
(2 g/kg). Because o f the prolonged increase in 
serum transaminase activities the cyclophos­
phamide pulse therapy was interrupted and 
the immunosuppression was changed to a 
combination o f oral prednisone, azathio- 
prine, and cyclosporine A, which slightly 
diminished disease activity but had no 
influence on neutropenia. A second bone 
marrow biopsy examination gave a similar 
result as described above. After two months 
the girl was admitted to hospital presenting 
with signs of sepsis and went into a coma and 
developed a progressive respiratory insuffi­
ciency. Thoracic and cranial computed 
tomography and nuclear magnetic resonance 
showed several abscess-like infiltrates in both 
lungs and brain, Antibiotic treatment, 
including amphotericine-B, was ineffective 
despite detection of aspergillus fumigatus 
infection by blood cultures. On the 
assumption diat neutropenia (740/f.il) is an 
important factor in the padiogenesis o f infec- 
don resistant to therapy, we started treatment 
widi rhG-CSF in a dose of 7.5 jig/kg/day over 
10 days. Before stardng rhG-CSF therapy the 
bone marrow aspirate showed a hypocellular- 
ity but no maturation arrest o f the myeloid 
series. The application of rhG-CSF had no 
effect on die number o f  peripheral 
neutrophils (about 600 cells/(,il). Subse­
quently die condition o f the girl worsened 
and the patient died in terminal respiratory 
insufficiency.
There are two reports demonstrating 
successful rhG-CSF treatment of neutro­
penia during SLE. In a 56 year old woman 
suffering from SLE and sepsis white blood 
cell count rose from 400/j.tl to 17 200 /jlI after 
treatment withlOO jxg/day rhG-CSF over live 
days.* The second report showed an increase 
of neutrophil counts in diree women (23-36  
years) with neutropenia during SLE after 
application of four cycles of 5 fcg/kg/day rhG- 
CSF from a mean of 1060 to 14 300 cells/j.il
within 48 hours. Fever of unknown origin 
subsided in all three cases, in addition, in one 
case a gluteal abscess healed after this 
treatment,2 In contrast with our case all of 
diese previously published case reports 
showed normal or increased granulopoiesis 
in bone marrow aspirates.21 The patients 
reported by Euler et al did not receive mediyl- 
prednisolone, cyclophosphamide or IgG 
pulse therapy, which may have influenced 
rhG-CSF stimulation on bone marrow cells 
in our patient by cytotoxic effects. However, 
neutropenia was present before immunosup­
pressive dierapy and bone marrow analysis 
did not change significantly during die 
course of disease. There are at least two pos­
sibilities that could explain the failure of 
rhG-CSF treatment in tliis case. ( 1) The 
block of myeloid cell production may have 
been located before rhG-CSF action on bone 
marrow cells. (2) Autoantibodies against 
rhG-CSF may inhibit the effects of tliis factor 
as described earlier for treatment widi erydi- 
ropoietin. Lack of maturation arrest in bone 
marrow analysis and die fact diat this was die 
first contact of our patient widi rhG-CSF do 
not support diese theories. Thus, die 
pathophysiological mechanisms leading to 
response or non-response of rhG-CSF treat­
ment in SLE associated neutropenia are still 
not clear.
In our opinion this case shows diat 
rhG-CSF application is not generally an 
effective treatment of SLE associated neutro­
penia. Hypocellularity of bone marrow 
aspirates and lack of prompt response seem 
to be a prognostic unfavourable factor 
regarding die beneficial effect of rhG-CSF 
treatment.
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